Valneva falls after Lyme disease vaccine data delay, outlook cut

Valneva SE

07/10/2025 09:56

** Shares in Valneva VLS.PA fall 7% after the French group delayed the release of Phase 3 Lyme disease vaccine data and cut its guidance for 2025

** Phase 3 data is now expected in H1 2026; according to three analysts, the release was previously expected in late 2025

** Valneva now sees annual revenue of 165-180 million euros ($193-210 million), vs 180-190 million euros previously, with R&D investments cut to 80-90 million euros from 90-100 million euros

** The shares are on track for their worst day in six weeks if the losses hold

($1 = 0.8566 euros)

(Reporting by Olivier Cherfan)

((olivier.cherfan@thomsonreuters.com))